Compare Amgen, Inc. (AMGN) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs CDW Corp. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while CDW Corp. trades at $144.74 (market cap $18.45B). The key difference: Amgen, Inc. is far larger — about 10.6× CDW Corp.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CDW | |
|---|---|---|
Market Cap | $196.12B | $18.45B |
Sector | Health | Technology |
52-Week High | $388.16 | $182.18 |
52-Week Low | $271.18 | $99.30 |
Enterprise Value | $241.41B | $23.66B |
Dividend Yield | 2.77% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CDW trades at $144.39, up 2.98% today, near its pivot point of $139 with resistance at $143. The stock shows strong profitability with a 44.16% ROE and consistent earnings beats in recent quarters. Recent news highlights AI infrastructure demand fueling growth, while the company increased its share repurchase program by $1 billion in May 2026. Technical indicators are bullish, with moving averages supporting upward momentum.
Outlook remains positive driven by AI demand and shareholder returns, but risks include margin pressure and high debt. Analysts are bullish with a $142.17 consensus target and 71% buy ratings. Investors should monitor Q2 2026 earnings against the $2.80 EPS estimate for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
